Goldman Sachs
AVIR icon

Goldman Sachs’s Atea Pharmaceuticals AVIR Stock Holding History

Goldman Sachs’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.47M Sell
530,856
-57,607
-10% -$287K ﹤0.01% 4511
2026
Q1 		$3.17M Buy
588,463
+115,941
+25% +$532K ﹤0.01% 4129
2025
Q4 		$1.69M Buy
472,522
+132,382
+39% +$421K ﹤0.01% 4737
2025
Q3 		$986K Buy
340,140
+40,483
+14% +$138K ﹤0.01% 5029
2025
Q2 		$1.08M Buy
299,657
+41,049
+16% +$122K ﹤0.01% 4639
2025
Q1 		$773K Sell
258,608
-53,527
-17% -$167K ﹤0.01% 4886
2024
Q4 		$1.05M Buy
312,135
+11,207
+4% +$37.2K ﹤0.01% 4791
2024
Q3 		$1.01M Buy
300,928
+79,586
+36% +$289K ﹤0.01% 4628
2024
Q2 		$733K Buy
221,342
+14,273
+7% +$53.2K ﹤0.01% 4610
2024
Q1 		$837K Sell
207,069
-21,771
-10% -$85.2K ﹤0.01% 4456
2023
Q4 		$698K Sell
228,840
-32,183
-12% -$97.5K ﹤0.01% 4574
2023
Q3 		$783K Sell
261,023
-44,698
-15% -$152K ﹤0.01% 4414
2023
Q2 		$1.14M Buy
305,721
+25,661
+9% +$96.1K ﹤0.01% 4262
2023
Q1 		$938K Buy
280,060
+36,843
+15% +$149K ﹤0.01% 4416
2022
Q4 		$1.17M Buy
243,217
+2,833
+1% +$14.3K ﹤0.01% 4322
2022
Q3 		$1.37M Buy
240,384
+13,164
+6% +$101K ﹤0.01% 4305
2022
Q2 		$1.61M Buy
227,220
+25,527
+13% +$174K ﹤0.01% 4228
2022
Q1 		$1.46M Sell
201,693
-77,875
-28% -$529K ﹤0.01% 4521
2021
Q4 		$2.5M Sell
279,568
-433,657
-61% -$6.76M ﹤0.01% 4061
2021
Q3 		$25M Buy
713,225
+333,001
+88% +$9.24M 0.01% 1864
2021
Q2 		$8.17M Buy
380,224
+126,036
+50% +$3.79M ﹤0.01% 2884
2021
Q1 		$15.7M Buy
254,188
+10,547
+4% +$713K ﹤0.01% 2147
2020
Q4 		$10.2M Buy
+243,641
New +$7.85M ﹤0.01% 2451

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs's AVIR Position: Q2 2026 in Review

Goldman Sachs reduced its Atea Pharmaceuticals (AVIR) stake by 9.8% in Q2 2026, selling an estimated $287K and leaving 530,856 shares worth $2.47M. The position accounts for ﹤0.01% of the portfolio, ranked #4511.

Goldman Sachs first reported a position in AVIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $25M in Q3 2021. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Goldman Sachs held 530,856 shares of Atea Pharmaceuticals worth $2.47M as of Q2 2026.
  • Goldman Sachs sold 57,607 Atea Pharmaceuticals shares in Q2 2026, an estimated $287K.
  • Atea Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4511 holding.
  • Goldman Sachs first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Goldman Sachs's Atea Pharmaceuticals position peaked at $25M in Q3 2021.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.